Updates to our Terms of Use

We are updating our Terms of Use. Please carefully review the updated Terms before proceeding to our website.

Saturday, April 13, 2024 | Back issues
Courthouse News Service Courthouse News Service

Pharma Class Action

Arrowhead Pharmaceuticals stock dropped from $9.36 to $1.44 after the failure of its three proposed drugs for liver disease, shareholders claim in a federal class action.

LOS ANGELES – Arrowhead Pharmaceuticals stock dropped from $9.36 to $1.44 after the failure of its three proposed drugs for liver disease, shareholders claim in a federal class action.

Categories / Business, Securities

Subscribe to Closing Arguments

Sign up for new weekly newsletter Closing Arguments to get the latest about ongoing trials, major litigation and hot cases and rulings in courthouses around the U.S. and the world.

Loading...